Lipoglycopeptide

Class of antibiotics

Lipoglycopeptides are a class of antibiotics that are structurally related to the glycopeptide antibiotics. They are characterized by the addition of a lipid moiety to the glycopeptide structure, which enhances their antibacterial activity and pharmacokinetic properties. Lipoglycopeptides are primarily used to treat serious Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Structure and Mechanism of Action

Lipoglycopeptides are derived from glycopeptides by the addition of a lipophilic side chain. This modification increases their ability to bind to the bacterial cell membrane, enhancing their antibacterial activity. The primary mechanism of action of lipoglycopeptides is the inhibition of bacterial cell wall synthesis. They achieve this by binding to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby preventing the cross-linking of peptidoglycan layers, which is essential for bacterial cell wall integrity.

Telavancin, a lipoglycopeptide antibiotic

In addition to inhibiting cell wall synthesis, lipoglycopeptides can also disrupt bacterial cell membrane function. The lipophilic side chain allows these antibiotics to insert into the bacterial membrane, causing depolarization and increased permeability, which can lead to cell death.

Clinical Uses

Lipoglycopeptides are used in the treatment of various serious infections caused by Gram-positive bacteria. These include:

• Complicated skin and skin structure infections (cSSSI)
• Hospital-acquired pneumonia (HAP)
• Ventilator-associated pneumonia (VAP)

They are particularly useful in treating infections caused by resistant strains of bacteria, such as MRSA and vancomycin-resistant Enterococcus (VRE).

Examples of Lipoglycopeptides

Several lipoglycopeptides have been developed and approved for clinical use. These include:

• Telavancin - Used for the treatment of cSSSI and HAP caused by Gram-positive bacteria.
• Dalbavancin - Known for its long half-life, allowing for less frequent dosing.
• Oritavancin - Effective against a broad range of Gram-positive bacteria, including resistant strains.

Pharmacokinetics

Lipoglycopeptides generally have favorable pharmacokinetic properties, including:

• Long half-lives, which allow for less frequent dosing schedules.
• Good tissue penetration, which is beneficial for treating deep-seated infections.
• Primarily renal excretion, which necessitates dose adjustments in patients with renal impairment.

Adverse Effects

Common adverse effects associated with lipoglycopeptides include:

• Nausea
• Vomiting
• Diarrhea
• Taste disturbance
• Foamy urine

Serious adverse effects can include nephrotoxicity and QT interval prolongation, which require careful monitoring during treatment.

Related Pages

• Antibiotic
• Glycopeptide antibiotic
• Methicillin-resistant Staphylococcus aureus
• Vancomycin